US development stage company TG Therapeutics (Nasdaq: TGTX) is trading higher again on Tuesday as investors continue to react to Monday’s news that the primary endpoint of its Phase III GENUINE study has been met.
The study was a trial of TG-1101 (ublituximab), a highly potent glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib, a drug marketed under the name Imbruvica from US companies AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ), in patients with previously treated high risk chronic lymphocytic leukemia (CLL).
"We believe the regimen has the potential to become the standard of care for patients with high-risk CLL that have progressed from other therapies"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze